| Literature DB >> 31477038 |
Chunmei Hu1, Lili Huang1, Min Cai2, Weixiao Wang3, Xudong Shi4, Wei Chen5.
Abstract
BACKGROUND: Environmental bacteria, nontuberculous mycobacteria (NTM), are recognized as one of the major human infection pathogens. NTM are prone to be mistaken as multidrug-resistant Mycobacterium tuberculosis and challenge our fight against TB. In addition, treatment of NTM per se is intractable. Remarkably, the distribution of NTM pathogenic species is geographically specific. Thus, it is very important to summarize the prevalent features and clinical symptoms of NTM pulmonary disease. However, In Nanjing district, southeast China, there is no such a report.Entities:
Keywords: Clinical symptom; Comorbidity; Nontuberculous mycobacteria; Prevalence; Pulmonary disease
Mesh:
Year: 2019 PMID: 31477038 PMCID: PMC6719376 DOI: 10.1186/s12879-019-4412-6
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Fig. 1Distribution of etiologic agents of NTM lung disease in Nanjing district of China from May 2017 to August 2018 (n = 87). M. abscessus represented the complex of M. chelonae ss. abscessus and M. chelonae
Fig. 2Demographic features of patients with NTM lung disease
Radiographic characteristics of different NTM species infection
| Presentations/No. of isolates | MAB ( | MAV ( | MKA ( | MIN ( | MGO ( | Total87 | Percent |
|---|---|---|---|---|---|---|---|
| Bronchiectasis | 7 | 2 | 4 | 20 | 1 | 34 | 39.1% |
| Pulmonary Cavity | 6 | 2 | 2 | 23 | 0 | 33 | 37.9% |
| Single cavity | 0 | 0 | 0 | 3 | 0 | 3 | 3.45% |
| Multiple cavities | 6 | 2 | 2 | 20 | 0 | 30 | 34.48% |
| Thick-walled cavity | 0 | 0 | 0 | 1 | 0 | 1 | 1.15% |
| Thin-walled cavity | 6 | 2 | 2 | 22 | 0 | 32 | 36.78% |
| Nodule | 5 | 4 | 2 | 22 | 0 | 33 | 37.9% |
| Lymphadenovarix | 2 | 2 | 0 | 12 | 0 | 16 | 18.3% |
| Pleural/Pericardial Effusion | 0 | 2 | 0 | 5 | 0 | 7 | 8.0% |
| Destroyed lungs | 0 | 0 | 0 | 3 | 0 | 3 | 3.4% |
| Pneumothorax | 0 | 0 | 1 | 1 | 0 | 2 | 2.3% |
| Total Percent | 32 16.5% | 16 8.2% | 13 6.7% | 132 68% | 1 0.5% | 194 |
MAB M. chelonae ss. abscessus and M. chelonae complex, MAV M. avium, MKA M. kansasii, MIN M. intracellulare, MGO M. gordonae
Clinical symptoms of NTM lung disease
| Symptoms No. of isolates | MAB ( | MAV ( | MKA ( | MIN ( | MGO ( | Total87 | Percent |
|---|---|---|---|---|---|---|---|
| Cough/Expectoration | 8 | 9 | 5 | 45 | 1 | 68 | 78.2% |
| Hemoptysis | 6 | 0 | 0 | 11 | 0 | 17 | 19.5% |
| Chest Congestion | 1 | 0 | 0 | 7 | 0 | 8 | 9.2% |
| Shortness of breath | 2 | 2 | 0 | 5 | 0 | 9 | 10.3% |
| Fever | 1 | 5 | 3 | 15 | 0 | 24 | 27.6% |
| Total | 18 | 16 | 8 | 83 | 1 | 126 | |
| Percent | 14.3% | 12.7% | 6.3% | 65.9% | 0.8% |
MAB M. chelonae ss. abscessus and M. chelonae complex, MAV M. avium, MKA M. kansasii, MIN M. intracellulare, MGO M. gordonae
Comorbidities of NTM lung disease
| Comorbidities No. of isolates | MAB ( | MAV ( | MKA ( | MIN ( | MGO ( | Total87 | Percent |
|---|---|---|---|---|---|---|---|
| Previous TB | 8 | 6 | 0 | 41 | 1 | 56 | 64.4% |
| Clinical Bronchiectasis | 6 | 0 | 0 | 11 | 0 | 17 | 19.5% |
| HIV positive | 0 | 8 | 4 | 5 | 0 | 17 | 19.5% |
| COPD | 0 | 0 | 1 | 5 | 0 | 6 | 6.9% |
| Hepatitis | 2 | 0 | 0 | 3 | 0 | 5 | 5.7% |
| DM | 0 | 0 | 0 | 4 | 0 | 4 | 4.6% |
| Hypertension | 1 | 0 | 0 | 3 | 0 | 4 | 4.6% |
| Cancer | 0 | 0 | 0 | 3 | 0 | 3 | 3.4% |
| AS | 0 | 1 | 0 | 0 | 0 | 1 | 1.1% |
| Pulmonary fibrosis | 1 | 0 | 0 | 3 | 0 | 4 | 4.6% |
| Total | 18 | 15 | 5 | 78 | 1 | 117 | |
| Percent | 15.4% | 12.8% | 4.3% | 66.7% | 0.9% |
MAB M. chelonae ss. abscessus and M. chelonae complex, MAV M. avium, MKA M. kansasii, MIN M. intracellulare, MGO M. gordonae. DM diabetes mellitus, COPD chronic obstructive pulmonary disease, AS Ankylosing
Comparison analysis of comorbidities and clinical features between patients with NTM disease and NTM colonization
| Confirmed case ( | Not meet ATS/IDSA criteria ( | |
|---|---|---|
| Male | 51 (58.6%) | 40 (59.7%) |
| Female | 36 (41.4%) | 27 (40.3%) |
| Age (median) | 60 (20–82) | 66 (19–87) |
| Radiographic characteristic | ||
| Cavity | 33 (37.9%) | 25 (37.3%) |
| Nodule | 33 (37.9%) | 28 (41.8%) |
| Bronchiectasis | 34 (39.1%) | 26 (38.8%) |
| Comorbidities | ||
| Previous TB | 56 (64.4%)* | 30 (44.8%)* |
| HIV positive | 17 (19.5%)* | 0* |
| Clinical features | ||
| Cough and Expectoration | 68 (78.1%) | 50 (74.6%) |
| Hemoptysis | 17 (19.5%) | 16 (23.9%) |
| Chest Congestion | 8 (9.2%) | 6 (9.0%) |
| Shortness of breath | 9 (10.3%) | 3 (4.5%) |
| Fever | 24 (27.6%)* | 9 (13.4%)* |
*indicates p < 0.05 for comparison between columns by Chi-square test